David Epstein, Seagen CEO
August 3, 2023 11:07 AM EDTUpdated 01:22 PM
Deals

Up­dat­ed: Seagen de­pri­or­i­tizes an­ti­body-drug can­di­date from $4.2B Mer­ck deal

Lei Lei Wu

News Reporter

Seagen has de­pri­or­i­tized work on ladi­ratuzum­ab ve­dotin, the biotech qui­et­ly dis­closed in its sec­ond quar­ter fi­nan­cial re­port Wednes­day.

Seagen has been …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump picks vac­cine skep­tic Kennedy to lead HHS, in what would be an up­heaval of US health pol­i­cy

Eu­ro­pean drug reg­u­la­tor re­vers­es opin­ion on Ei­sai and Bio­gen's Alzheimer's drug

Gilead will close Philadel­phia, Seat­tle of­fices as part of job re­duc­tions

BeiGene will re­brand to BeOne Med­i­cines, drop­ping name's link to Chi­na roots

Mer­ck buys in­to PD-1/VEGF space as Sum­mit comes for Keytru­da

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times